TP53 ‐altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity
2022; Wiley; Volume: 129; Issue: 2 Linguagem: Inglês
10.1002/cncr.34535
ISSN1097-0142
AutoresRory M. Shallis, Naval Daver, Jessica K. Altman, Robert P. Hasserjian, Hagop M. Kantarjian, Uwe Platzbecker, Valeria Santini, Andrew H. Wei, David A. Sallman, Amer M. Zeidan,
Tópico(s)Hematopoietic Stem Cell Transplantation
ResumoAbstract TP5 3 ‐altered myelodysplastic syndrome with excess blasts and TP53 ‐altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.
Referência(s)